Shots:
- The US FDA has approved & granted interchangeability designation to Omlyclo, a biosimilar to Xolair (omalizumab) for the treatment of mod. to sev. persistent asthma, CRSwNP, IgE-mediated food allergy, & chronic spontaneous urticaria (CSU)
- Approval was based on multiple clinical evidence, incl. P-III trial assessing Omlyclo (150mg, Q4W) vs Xolair (300mg, Q4W) in 619 CSU pts for 12wks., followed by re-randomization of comparator arm to Omlyclo or Xolair. From Wk. 24, pts were monitored without dosing until Wk. 40
- Study demonstrated interchangeability with reference product, showing comparable efficacy & safety during both treatment & off-dose period
Ref: Celltrion | Image: Celltrion
Related News:- Celltrion Reports the US FDA approval for Stoboclo & Osenvelt (Biosimilars, Prolia & Xgeva)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
